Novel amide and amidine derivates and uses thereof
申请人:Abbott Laboratories
公开号:EP2243479A2
公开(公告)日:2010-10-27
The present invention relates to inhibitors of 11- β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
申请人:The Liver Company Inc.
公开号:US11136290B2
公开(公告)日:2021-10-05
Provided is a compound of Formula (I):
wherein the variable groups are defined herein.
提供的是一种式 (I) 化合物:
其中变量组在此定义。
SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES
申请人:GILEAD SCIENCES, INC.
公开号:EP3796975A1
公开(公告)日:2021-03-31
US8507493B2
申请人:——
公开号:US8507493B2
公开(公告)日:2013-08-13
[EN] NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS AMIDE ET AMIDINE ET LEURS UTILISATIONS
申请人:ABBOTT LAB
公开号:WO2010123838A2
公开(公告)日:2010-10-28
The present invention relates to inhibitors of 11- β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.